**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Elyn Montgomery
Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.
St Vincent’s Amyloidosis Centre, St Vincent’s Hospital, Darlinghurst, New South Wales, Australia.
Faculty of Health, University of Technology Sydney, Ultimo, New South Wales, Australia.

**Main Body of the Abstract**
BACKGROUND:
Frailty is a multidimensional syndrome of decreased physiological reserve, characterised by a heightened vulnerability to stressors and has demonstrated prognostic significance across several cardiovascular conditions such as transthyretin amyloid cardiomyopathy (ATTR-CM).
Our aim was to assess the prevalence of frailty and the association with disease severity in patients with ATTR-CM.
METHODS:
The Clinical Frailty Scale (CFS) is a clinical judgement-based tool which evaluates specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill). The CFS was used to retrospectively assess frailty in consecutive patients diagnosed with ATTR-CM at the St Vincent’s Amyloidosis Centre Sydney. Frailty was defined as a CFS ≥5. In addition, markers of disease severity were obtained.
RESULTS:
Seventy patients (62M:8F; age, median 79 years, interquartile range 10) underwent frailty assessment. Frailty was confirmed in 34/70 (48%) and was associated with increased interventricular septal diameter (p=0.008), Gilmore Stage (p=0.05) and New York Heart Association functional classification (NYHA)(p<0.001). There was no association between frailty and age, gender, or renal impairment.
CONCLUSIONS:
Frailty is prevalent among patients with ATTR-CM. It is associated with markers of advanced disease including NYHA and Gilmore stage.  Frailty screening in ATTR-CM has the potential to enhance risk stratification and improve selection criteria for novel disease-modifying therapies.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Elyn Montgomery
1. Victor Chang Cardiac Research Institute, Darlinghurst, New South Wales, Australia.
2. St Vincent’s Amyloidosis Centre, St Vincent’s Hospital, Darlinghurst, New South Wales, Australia.
3. Faculty of Health, University of Technology Sydney, Ultimo, New South Wales, Australia.

**Main Body of the Abstract**
**BACKGROUND:**
Frailty is a multidimensional syndrome of decreased physiological reserve, characterised by a heightened vulnerability to stressors and has demonstrated prognostic significance across several cardiovascular conditions such as transthyretin amyloid cardiomyopathy (ATTR-CM).
Our aim was to assess the prevalence of frailty and the association with disease severity in patients with ATTR-CM.
**METHODS:**
The Clinical Frailty Scale (CFS) is a clinical judgement-based tool which evaluates specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill). The CFS was used to retrospectively assess frailty in consecutive patients diagnosed with ATTR-CM at the St Vincent’s Amyloidosis Centre Sydney. Frailty was defined as a CFS ≥5. In addition, markers of disease severity were obtained.
**RESULTS:**
Seventy patients (62M:8F; age, median 79 years, interquartile range 10) underwent frailty assessment. Frailty was confirmed in 34/70 (48%) and was associated with increased interventricular septal diameter (p=0.008), Gilmore Stage (p=0.05) and New York Heart Association functional classification (NYHA)(p<0.001). There was no association between frailty and age, gender, or renal impairment.
**CONCLUSIONS:**
Frailty is prevalent among patients with ATTR-CM. It is associated with markers of advanced disease including NYHA and Gilmore stage.  Frailty screening in ATTR-CM has the potential to enhance risk stratification and improve selection criteria for novel disease-modifying therapies.



The prevalence of frailty and association with disease severity in transthyretin amyloid cardiomyopathy PC40 (#265)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.